An experimental drug intended to enable tooth decay in humans has entered the clinical testing phase, opening up new opportunities for treating tooth loss.

The study is under way at the Tokyo University Hospital, where 30 men aged 30 to 64 who lack at least one tooth are taking the medicine through intravenous infusion.

Research is based on a protein called USAG-1, which prevents the development of new teeth. The medicine aims to block the action of this protein by activating the tooth regeneration process.

In previous tests, developed in rats and thorns, the blocking of this protein has promoted new teeth – results that have encouraged researchers to continue with human evidence.

Currently, the first phase of the study is focused on the safety of the medicine and the assessment of its effects. If the results are positive, researchers aim for treatment to be available to patients by 2030.

If this technology is able to prove its effectiveness, the future loss of teeth may not necessarily mean the need for prosthetics or implants, but the possibility of new teeth growing.

The signal where the truth speaks before the news!

/Gazeta Sinjali/

Source Layer: Signal